Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Table 2 Suggested preference of pharmacotherapy in type 2 diabetes based on cardiovascular effects

Acceptable	Avoid	No data
Established or at risk of heart failure
Metformin	TZDs	Meglitinides
Sulfonylureas	DPP-4 inhibitors^a	AGIs
SGLT-2 inhibitors
Established cardiovascular disease
Metformin	1st generation sulfonylureas	Meglitinides
2nd and 3rd generation sulfonylureas	Rosiglitazone	AGIs
Pioglitazone
DPP-4 inhibitors
SGLT-2 inhibitors

TZDs thiazolidinediones, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, SGLT-2 sodium glucose cotransporter 2, AGIs alpha-glucosidase inhibitors
^aSpecifically saxagliptin and alogliptin; note that sitagliptin may be used

ISSN: 1475-2840